...
【24h】

Bevacizumab and ovarian cancer.

机译:贝伐单抗和卵巢癌。

获取原文
获取原文并翻译 | 示例
           

摘要

Epithelial ovarian cancer is the most lethal of gynecologic malignancies in the United States, with a significant proportion of patients with advanced disease achieving clinical remission with conventional treatment approaches, but dying of recurrence. Bevacizumab is a first-in-class antiangiogenic. This recombinant humanized monoclonal antibody neutralizes vascular endothelial growth factor (VEGF) and inhibits endothelial and tumor cell activation and proliferation. It has a low clearance and long elimination half-life, supporting a convenient 2- or 3-weekly dosing schedule. It is generally well tolerated, although trials have highlighted some toxicity-related concerns, notably gastrointestinal perforation. Phase III trials that evaluate overall survival are not yet mature, and cost-effectiveness of bevacizumab is hotly debated. As more evidence for the role of anti-VEGF agents in augmenting therapy and inducing durable tumor dormancy continues to emerge, it is anticipated that antiangiogenic therapy will play an important role in the management ovarian malignancy.
机译:在美国,上皮性卵巢癌是最致命的妇科恶性肿瘤,相当一部分患有晚期疾病的患者通过常规治疗方法可达到临床缓解,但死于复发。贝伐单抗是一流的抗血管生成药物。这种重组人源化单克隆抗体可中和血管内皮生长因子(VEGF),并抑制内皮和肿瘤细胞的活化和增殖。它具有较低的清除率和较长的消除半衰期,支持方便的每周2或3次给药计划。尽管试验已经强调了一些与毒性有关的问题,尤其是胃肠道穿孔,但通常耐受性良好。评估总体存活率的III期临床研究尚未成熟,贝伐单抗的成本效益受到了激烈的争论。随着越来越多的证据表明抗血管内皮生长因子药物在增强治疗和诱导持久性肿瘤休眠中的作用不断出现,预计抗血管生成治疗将在控制卵巢恶性肿瘤中发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号